Difficulty: Medium
Average Score: 77%
Practice
Omalizumab:
Correct answer
C
Rationale
Rationale:
The correct answer is C) Is administered by subcutaneous injection.
Omalizumab is a monoclonal antibody used to treat allergic conditions like asthma and chronic idiopathic urticaria. It works by binding to free IgE in the blood, preventing it from triggering allergic reactions. Omalizumab is administered by subcutaneous injection because it needs to be delivered directly into the tissue below the skin to be effective. This route allows for slow and controlled absorption, ensuring the medication reaches the bloodstream gradually for optimal results.
Option A) Is contraindicated in patients with IgE-mediated sensitivity to inhaled allergen is incorrect because omalizumab is actually used to treat conditions associated with IgE-mediated allergies, not contraindicated for them.
Option B) Is used to treat severe acute attacks is incorrect because omalizumab is not typically used for the treatment of acute attacks, but rather for long-term management and prevention of allergic conditions.
Option D) Inhibits warfarin metabolism via CYP 2C9 is incorrect because omalizumab does not have a direct interaction with warfarin metabolism via CYP 2C9. This statement is not relevant to the mechanism of action or administration of omalizumab.
Educational Context:
Understanding the correct administration route of medications is crucial for healthcare professionals to ensure the safe and effective delivery of treatment to patients. Knowing that omalizumab is administered by subcutaneous injection helps healthcare providers in properly administering the medication, monitoring for potential side effects, and educating patients on self-administration techniques if applicable. This knowledge contributes to improved patient outcomes and medication adherence in the management of allergic conditions.
The correct answer is C) Is administered by subcutaneous injection.
Omalizumab is a monoclonal antibody used to treat allergic conditions like asthma and chronic idiopathic urticaria. It works by binding to free IgE in the blood, preventing it from triggering allergic reactions. Omalizumab is administered by subcutaneous injection because it needs to be delivered directly into the tissue below the skin to be effective. This route allows for slow and controlled absorption, ensuring the medication reaches the bloodstream gradually for optimal results.
Option A) Is contraindicated in patients with IgE-mediated sensitivity to inhaled allergen is incorrect because omalizumab is actually used to treat conditions associated with IgE-mediated allergies, not contraindicated for them.
Option B) Is used to treat severe acute attacks is incorrect because omalizumab is not typically used for the treatment of acute attacks, but rather for long-term management and prevention of allergic conditions.
Option D) Inhibits warfarin metabolism via CYP 2C9 is incorrect because omalizumab does not have a direct interaction with warfarin metabolism via CYP 2C9. This statement is not relevant to the mechanism of action or administration of omalizumab.
Educational Context:
Understanding the correct administration route of medications is crucial for healthcare professionals to ensure the safe and effective delivery of treatment to patients. Knowing that omalizumab is administered by subcutaneous injection helps healthcare providers in properly administering the medication, monitoring for potential side effects, and educating patients on self-administration techniques if applicable. This knowledge contributes to improved patient outcomes and medication adherence in the management of allergic conditions.